Halozyme Therapeutics Inc annual ebitda for fiscal 2025 was $573 million, a decrease of 12.8% from $657 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $573M | $657M | $452M | $316M | $279M | $148M | ($64M) | ($67M) | $83M | ($81M) | ($26M) | ($61M) | ($79M) | ($53M) | ($19M) | ($53M) | ($57M) | ($49M) | ($28M) | ($15M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| EBITDA | — | $220M | ($69M) | $244M | $230M | $169M | $203M | $190M | $143M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More HALO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All HALO financial statements → Interactive HALO charts →
About TickerBase · Data methodology & sources · Privacy · Terms